Human interleukin-2
- Generic Name
- Human interleukin-2
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FNO32LO217
- Background
Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
- Associated Conditions
- -
- Associated Therapies
- -
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
- Conditions
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- BGI, China
- Target Recruit Count
- 21
- Registration Number
- NCT05798546
- Locations
- 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Quadruple Immunotherapy for Neuroblastoma
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Hong Kong Children's Hospital
- Target Recruit Count
- 29
- Registration Number
- NCT05754684
- Locations
- 🇭🇰
Hong Kong Children's Hospital, Hong Kong, Hong Kong
TIL Cells for the Treatment of the Advanced Solid Tumors Patients
- Conditions
- Interventions
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT05649618
TCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05648994
The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LN
- Conditions
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2022-11-30
- Target Recruit Count
- 40
- Registration Number
- NCT05631717
- Locations
- 🇨🇳
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-11-27
- Target Recruit Count
- 25
- Registration Number
- NCT05628883
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
- Conditions
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2022-11-02
- Lead Sponsor
- Second Affiliated Hospital of Soochow University
- Target Recruit Count
- 45
- Registration Number
- NCT05603013
- Locations
- 🇨🇳
Second Affiliated Hospital of Soochow University, Suzhou, China
PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.
- Conditions
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Second Affiliated Hospital of Soochow University
- Target Recruit Count
- 56
- Registration Number
- NCT05530200
Interleukin-2 on Active Dermatomyositis
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT05495321
- Locations
- 🇨🇳
Peking university people's hospital, Beijing, Beijing, China
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Jennifer Eva Selfridge, MD
- Target Recruit Count
- 12
- Registration Number
- NCT05400122
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.